PRECIGEN, INC. Research and Development Expense
PRECIGEN, INC. (PGEN) reported Research and Development Expense of $7.28 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-04
- PRECIGEN, INC. research and development expense for the quarter ending 2026-06-30 was $7.28M, a 36.61% decline year-over-year.
- PRECIGEN, INC. research and development expense for the quarter ending 2026-03-31 was $5.64M, a 46.19% decline year-over-year.
- PRECIGEN, INC. research and development expense for the quarter ending 2025-06-30 was $11.49M.
- PRECIGEN, INC. research and development expense for the quarter ending 2025-03-31 was $10.48M.
- PRECIGEN, INC. research and development expense for fiscal 2025 was $41.33M, a 22.12% decline from fiscal 2024.
- PRECIGEN, INC. research and development expense for fiscal 2024 was $53.07M, a 9.17% increase from fiscal 2023.
- PRECIGEN, INC. research and development expense for fiscal 2023 was $48.61M.
- PRECIGEN, INC. research and development expense for fiscal 2018 was $404.59M, a 182.52% increase from fiscal 2017.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $7.28M 10-Q · filed 2026-08-04 | $12.92M 10-Q · filed 2026-08-04 | ||||||
| 2026-03-31 | $5.64M 10-Q · filed 2026-05-13 | |||||||
| 2025-12-31 | $41.33M 10-K · filed 2026-03-25 | |||||||
| 2025-06-30 | $11.49M 10-Q · filed 2026-08-04 | $21.97M 10-Q · filed 2026-08-04 | ||||||
| 2025-03-31 | $10.48M 10-Q · filed 2026-05-13 | |||||||
| 2024-12-31 | $53.07M 10-K · filed 2026-03-25 | |||||||
| 2023-12-31 | $48.61M 10-K · filed 2026-03-25 | |||||||
| 2019-09-30 | $31.48M 10-Q · filed 2019-11-12 | $66.00M derived: sum of 2 quarters · filed 2019-11-12 | $99.06M 10-Q · filed 2019-11-12 | $379.57M derived: sum of 4 quarters · filed 2019-11-12 | ||||
| 2019-06-30 | $34.52M 10-Q · filed 2019-08-09 | $67.58M 10-Q · filed 2019-08-09 | $348.09M derived: sum of 3 quarters · filed 2019-08-09 | $392.98M derived: sum of 4 quarters · filed 2019-11-12 | ||||
| 2019-03-31 | $33.06M 10-Q · filed 2019-05-09 | $313.58M derived: sum of 2 quarters · filed 2019-05-09 | $358.46M derived: sum of 3 quarters · filed 2019-11-12 | $400.51M derived: sum of 4 quarters · filed 2019-11-12 | ||||
| 2018-12-31 | $280.51M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $325.40M derived: sum of 2 quarters · filed 2019-11-12 | $367.45M derived: sum of 3 quarters · filed 2019-11-12 | $404.59M 10-K · filed 2019-03-01 | ||||
| 2018-09-30 | $44.88M 10-Q · filed 2019-11-12 | $86.93M derived: sum of 2 quarters · filed 2019-11-12 | $124.07M 10-Q · filed 2019-11-12 | $162.75M derived: sum of 4 quarters · filed 2019-11-12 | ||||
| 2018-06-30 | $42.05M 10-Q · filed 2019-08-09 | $79.19M 10-Q · filed 2019-08-09 | $117.86M derived: sum of 3 quarters · filed 2019-08-09 | $154.33M derived: sum of 4 quarters · filed 2019-08-09 | ||||
| 2018-03-31 | $37.27M 10-Q · filed 2019-05-09 | $75.81M derived: sum of 2 quarters · filed 2019-05-09 | $112.28M derived: sum of 3 quarters · filed 2019-05-09 | $146.29M derived: sum of 4 quarters · filed 2019-05-09 | ||||
| 2017-12-31 | $38.54M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $75.02M derived: sum of 2 quarters · filed 2019-03-01 | $109.03M derived: sum of 3 quarters · filed 2019-03-01 | $143.21M 10-K · filed 2019-03-01 | ||||
| 2017-09-30 | $36.47M 10-Q · filed 2018-11-08 | $70.48M derived: sum of 2 quarters · filed 2018-11-08 | $104.66M 10-Q · filed 2018-11-08 | $133.53M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2017-06-30 | $34.01M 10-Q · filed 2018-08-13 | $68.19M 10-Q · filed 2018-08-13 | $97.06M derived: sum of 3 quarters · filed 2019-03-01 | $126.09M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2017-03-31 | $34.18M 10-Q/A · filed 2018-08-13 | $63.05M derived: sum of 2 quarters · filed 2019-03-01 | $92.08M derived: sum of 3 quarters · filed 2019-03-01 | $120.46M derived: sum of 4 quarters · filed 2019-03-01 | ||||
| 2016-12-31 | $28.87M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $57.90M derived: sum of 2 quarters · filed 2019-03-01 | $86.28M derived: sum of 3 quarters · filed 2019-03-01 | $112.14M 10-K · filed 2019-03-01 | ||||
| 2016-09-30 | $29.04M 10-Q · filed 2017-11-09 | $57.41M derived: sum of 2 quarters · filed 2017-11-09 | $83.27M 10-Q · filed 2017-11-09 | $109.46M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2016-06-30 | $28.38M 10-Q · filed 2017-08-09 | $54.23M 10-Q · filed 2017-08-09 | $80.43M derived: sum of 3 quarters · filed 2018-03-01 | $102.03M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2016-03-31 | $25.86M 10-Q · filed 2017-05-10 | $52.05M derived: sum of 2 quarters · filed 2018-03-01 | $73.65M derived: sum of 3 quarters · filed 2018-03-01 | $94.03M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2015-12-31 | $26.20M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $47.80M derived: sum of 2 quarters · filed 2018-03-01 | $68.18M derived: sum of 3 quarters · filed 2018-03-01 | $147.48M 10-K · filed 2018-03-01 | ||||
| 2015-09-30 | $21.60M 10-Q · filed 2016-11-09 | $41.98M derived: sum of 2 quarters · filed 2016-11-09 | $121.29M 10-Q · filed 2016-11-09 | $138.93M derived: sum of 4 quarters · filed 2017-03-01 | ||||
| 2015-06-30 | $20.38M 10-Q · filed 2016-08-09 | $99.69M 10-Q · filed 2016-08-09 | $117.33M derived: sum of 3 quarters · filed 2017-03-01 | $132.18M derived: sum of 4 quarters · filed 2017-03-01 | ||||
| 2015-03-31 | $79.31M 10-Q · filed 2016-05-10 | $96.95M derived: sum of 2 quarters · filed 2017-03-01 | $111.80M derived: sum of 3 quarters · filed 2017-03-01 | $126.23M derived: sum of 4 quarters · filed 2017-03-01 | ||||
| 2014-12-31 | $17.64M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $32.49M derived: sum of 2 quarters · filed 2017-03-01 | $46.92M derived: sum of 3 quarters · filed 2017-03-01 | $58.98M 10-K · filed 2017-03-01 | ||||
| 2014-09-30 | $14.85M 10-Q · filed 2015-11-09 | $29.29M derived: sum of 2 quarters · filed 2015-11-09 | $41.34M 10-Q · filed 2015-11-09 | $53.89M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-06-30 | $14.43M 10-Q · filed 2015-08-10 | $14.48M 10-Q · filed 2014-08-14 | $26.49M 10-Q · filed 2015-08-10 | $26.57M 10-Q · filed 2014-08-14 | $39.04M derived: sum of 3 quarters · filed 2016-02-29 | $49.80M derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2014-03-31 | $12.06M 10-Q · filed 2015-05-11 | $12.09M 10-Q · filed 2014-05-09 | $24.61M derived: sum of 2 quarters · filed 2016-02-29 | $35.37M derived: sum of 3 quarters · filed 2016-02-29 | $48.88M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2013-12-31 | $12.55M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $23.31M derived: sum of 2 quarters · filed 2016-02-29 | $36.82M derived: sum of 3 quarters · filed 2016-02-29 | $48.14M 10-K · filed 2016-02-29 | $48.16M 10-K · filed 2014-03-31 | |||
| 2013-09-30 | $10.67M 10-Q · filed 2014-11-13 | $24.27M derived: sum of 2 quarters · filed 2014-08-14 | $35.59M 10-Q · filed 2014-11-13 | $35.87M 10-Q · filed 2013-11-07 | $48.73M derived: sum of 4 quarters · filed 2015-03-02 | |||
| 2013-06-30 | $13.51M 10-Q · filed 2014-08-14 | $13.60M 10-Q/A · filed 2013-10-21 | $24.92M 10-Q · filed 2014-08-14 | $25.10M 10-Q/A · filed 2013-10-21 | $37.97M derived: sum of 3 quarters · filed 2015-03-02 | $52.34M derived: sum of 4 quarters · filed 2015-03-02 | ||
| 2013-03-31 | $11.41M 10-Q · filed 2014-05-09 | $24.46M derived: sum of 2 quarters · filed 2015-03-02 | $38.83M derived: sum of 3 quarters · filed 2015-03-02 | $56.47M derived: sum of 4 quarters · filed 2015-03-02 | ||||
| 2012-12-31 | $13.05M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $27.41M derived: sum of 2 quarters · filed 2015-03-02 | $45.05M derived: sum of 3 quarters · filed 2015-03-02 | $64.03M 10-K · filed 2015-03-02 | ||||
| 2012-09-30 | $14.36M 10-Q · filed 2013-11-07 | $32.01M derived: sum of 2 quarters · filed 2013-11-07 | $50.98M 10-Q · filed 2013-11-07 | |||||
| 2012-06-30 | $17.64M 10-Q/A · filed 2013-10-21 | $36.62M 10-Q/A · filed 2013-10-21 | ||||||
| 2011-12-31 | $70.23M 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |